Duloxetine delayed-release capsules recalled for N-nitroso impurity contamination
Breckenridge Pharmaceutical is recalling Duloxetine Delayed-Release Capsules 60mg due to the presence of N-nitroso-duloxetine impurity above FDA recommended limits. The affected product was distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The source indicates an FDA Class II recall with a manufacturing (CGMP) deviation and impurity above recommended limits. The source text does not report any illnesses or injuries, and the hazard is related to manufacturing control rather than an acute safety threat, consistent with a Moderate severity classification.
Plain-English summary
Breckenridge Pharmaceutical, Inc. is recalling Duloxetine Delayed-Release Capsules USP, 60mg (90-count bottles) due to the presence of N-nitroso-duloxetine impurity above the FDA recommended limit. The product was manufactured by TOWA Pharmaceutical Europe S.L. in Martorelles, Barcelona, Spain, and distributed by Breckenridge Pharmaceutical, Inc. in Berkeley Heights, New Jersey. The recalled lot is 241069C with an expiration date of 05/31/2027.
Approximately 165,761 90-count bottles were distributed nationwide in the USA. This is a Class II recall. Patients taking this medication should consult their healthcare provider before discontinuing use or switching to an alternative treatment. Healthcare providers and patients with questions may contact Breckenridge Pharmaceutical for additional information.
The recalled product
- Product
- DULOXETINE (DULOXETINE HYDROCHLORIDE)
- Brand
- DULOXETINE
- Manufacturer
- Breckenridge Pharmaceutical, Inc.
- Category
- Drug — Antidepressant / SNRI
- Hazard
- n-nitroso-impurity
- manufacturing-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot: 241069C
- Exp 05/31/2027
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · DULOXETINE
- ModerateDuloxetine Delayed-Release Capsules Recalled for Impurity Above Limit
FDA (Drugs) · 2026-05-13
- ModerateDuloxetine Delayed-Release Capsules 20 mg Recalled for Impurity
FDA (Drugs) · 2026-05-13
- ModerateDuloxetine Delayed-Release Capsules Recalled for Impurity Above FDA Limit
FDA (Drugs) · 2026-05-13
- HighPrescription Duloxetine Capsules Recalled for Nitrosamine Impurity
FDA (Drugs) · 2025-04-09
- HighDuloxetine 60mg Capsule Recall Due to Manufacturing Impurity
FDA (Drugs) · 2025-03-19
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereAccucaine Lidocaine Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2026-07-08
- SevereChloraPrep One-Step Antiseptic Applicators recalled for lack of sterility assurance
FDA (Drugs) · 2026-07-08
- SevereChloraPrep One-Step Sterile Solution Lacks Assurance of Sterility
FDA (Drugs) · 2026-07-08
- ModerateMedline Ophthalmic Pack with Lidocaine Injection Kits Recalled
FDA (Devices) · 2026-07-08